[1]
|
耿广勇, 王文斌, 陆震, 袁笑, 徐阿曼, 刘付宝. 巨大肝癌手术疗效及影响预后的因素分析[J]. 肝胆外科杂志, 2022, 30(3): 190-194.
|
[2]
|
Ren, Z., Ducreux, M., Abou-Alfa, G.K., Merle, P., Fang, W., Edeline, J., Li, Z., Wu, L., Assenat, E., Hu, S., et al. (2023) Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer, 12, 72-84.
https://doi.org/10.1159/000527175
|
[3]
|
Merle, P., Kudo, M., Edeline, J., Bouattour, M., Cheng, A.L., Chan, S.L., Yau, T., Garrido, M., Knox, J., Daniele, B., et al. (2023) Pembrolizumab as Second-Line Therapy for Advanced Hepa-tocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 12, 309-320. https://doi.org/10.1159/000529636
|
[4]
|
Kelley, R.K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.K., Qin, S., Tai, D.W., Lim, H.Y., Yau, T., et al. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001.
https://doi.org/10.1200/JCO.20.03555
|
[5]
|
Galle, P.R., Finn, R.S., Qin, S., Ikeda, M., Zhu, A.X., Kim, T.Y., Kudo, M., Breder, V., Merle, P., Kaseb, A., et al. (2021) Patient-Reported Outcomes with Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 991-1001. https://doi.org/10.1016/S1470-2045(21)00151-0
|
[6]
|
国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会(CSCO)肝癌专家委员会. 肝细胞癌免疫联合治疗多学科中国专家共识(2023版) [J]. 中华肝脏病杂志, 2023, 31(1): 16-34.
https://doi.org/10.3760/cma.j.cn501113-20221215-00602
|
[7]
|
Kudo, M. (2022) Durvalumab plus Tremelimumab in Unresectable Hepatocellular Carcinoma. Hepatobiliary Surgery and Nutrition, 11, 592-596. https://doi.org/10.21037/hbsn-22-143
|
[8]
|
Song, X., Kelley, R.K., Khan, A.A., Standifer, N., Zhou, D., Lim, K., Krishna, R., Liu, L., Wang, K., McCoon, P., et al. (2023) Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 29, 754-763.
https://doi.org/10.1158/1078-0432.CCR-22-1983
|
[9]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[10]
|
Vogel, A., Meyer, T., Sapisochin, G., Salem, R. and Saborowski, A. (2022) Hepatocellular Carcinoma. The Lancet, 400, 1345-1362. https://doi.org/10.1016/S0140-6736(22)01200-4
|
[11]
|
Byeon, J., Cho, E.H., Kim, S.B. and Choi, D.W. (2012) Ex-trahepatic Recurrence of Hepatocellular Carcinoma after Curative Hepatic Resection. Korean Journal of Hepa-to-Biliary-Pancreatic Surgery, 16, 93-97.
https://doi.org/10.14701/kjhbps.2012.16.3.93
|
[12]
|
Yoh, T., Seo, S., Taura, K., Iguchi, K., Ogiso, S., Fukumitsu, K., Ishii, T., Kaido, T. and Uemoto, S. (2021) Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-Term Sur-vival. Annals of Surgery, 273, 792-799.
https://doi.org/10.1097/SLA.0000000000003358
|
[13]
|
陶常诚, 张凯, 荣维淇, 吴健雄. 肝细胞癌根治术后早期复发及其时间点的研究进展[J]. 肿瘤防治研究, 2022, 49(4): 359-363.
|
[14]
|
曹俊宁, 张雯雯, 赵海涛, 毕新宇. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版) [J]. 肝癌电子杂志, 2021, 8(2): 6-15.
|
[15]
|
Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[16]
|
Finn, R.S., Ikeda, M., Zhu, A.X., Sung, M.W., Baron, A.D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) Phase Ib Study of Lenvatinib plus Pem-brolizumab in Patients with Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 38, 2960-2970. https://doi.org/10.1200/JCO.20.00808
|
[17]
|
Kudo, M., Ikeda, M., Motomura, K., Okusaka, T. and Kobayashi, M. (2020) A Phase Ib Study of Lenvatinib (LEN) plus Nivolumab (NIV) in Patients (pts) with Unresectable Hepatocellular Carcinoma (uHCC): Study 117. Journal of Clinical Oncology, 38, 513-513. https://doi.org/10.1200/JCO.2020.38.4_suppl.513
|
[18]
|
Shen, L., Zhang, Y., Guo, Y., Li, W. and Tse, A. (2020) 987P A Phase Ib Study of the PD-1 Antagonist CS1003 plus Lenvatinib (LEN) in Chinese Patients (pts) with the First-Line (1L) Unresectable Hepatocellular Carcinoma (uHCC). Annals of Oncology, 31, S690-S691. https://doi.org/10.1016/j.annonc.2020.08.1103
|
[19]
|
杨欣荣, 孙惠川, 谢青, 张万广, 荚卫东, 赵明, 赵海涛, 刘秀峰, 周乐杜, 严盛, 等. 仑伐替尼肝癌全病程应用中国专家指导意见[J]. 中华消化外科杂志, 2023, 22(2): 167-180.
|
[20]
|
Cammarota, A., Zanuso, V., D’Alessio, A., Pressiani, T., Personeni, N. and Rimassa, L. (2022) Cabozantinib plus Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma: Shedding Light on the Pre-clinical Rationale and Clinical Trials. Expert Opinion on Investigational Drugs, 31, 401-413.
https://doi.org/10.1080/13543784.2022.2032641
|
[21]
|
Kelley, R.K., Rimassa, L., Cheng, A.L., Kaseb, A., Qin, S., Zhu, A.X., Chan, S.L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) Cabozantinib plus Atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 23, 995-1008.
https://doi.org/10.1016/S1470-2045(22)00326-6
|
[22]
|
Llovet, J.M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.Y., Ren, Z., et al. (2023) Lenvatinib plus Pembrolizumab versus Lenvatinib plus Place-bo for Advanced Hepatocellular Carcinoma (LEAP-002): A Randomised, Double-Blind, Phase 3 Trial. The Lancet On-cology, 24, 1399-1410.
|
[23]
|
Zhu, X.D., Huang, C., Shen, Y.H., Ji, Y., Ge, N.L., Qu, X.D., Chen, L., Shi, W.K., Li, M.L., Zhu, J.J., et al. (2021) Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyro-sine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 10, 320-329. https://doi.org/10.1159/000514313
|
[24]
|
孙惠川, 谢青, 荚卫东, 赵明, 刘秀峰, 毕新宇, 黎功, 白雪莉, 纪元, 徐立, 等. 肝癌转化治疗中国专家共识(2021版) [J]. 中国实用外科杂志, 2021, 41(6): 618-632. https://doi.org/10.19538/j.cjps.issn1005-2208.2021.06.02
|
[25]
|
Chen, X., Zhang, Y., Zhang, N., Ge, Y. and Jia, W. (2019) Lenvatinib Combined Nivolumab Injection Followed by Extended Right Hepatectomy Is a Feasible Treatment for Patients with Massive Hepatocellular Carcinoma: A Case Report. OncoTargets and Therapy, 12, 7355-7359. https://doi.org/10.2147/OTT.S217123
|